Medline Inc.
Medline Inc. (MDLN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
mdln · stock forecast · 14 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 14 Wall Street analysts in the past 3 months
Buy
14 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$60.00
Consensus
$48.55
+44.5% upside
Low
$38.00
Median: $48 · Last Close: $33.61
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$48.55
44.5% upside
High Target
$60
78.5%
Low Target
$38
13.1%
Current Price
$33.61
as of today
Based on analyst price targets, the MDLN stock price prediction for the next 12 months ranges from $38 to $60. The consensus MDLN price forecast of $48.55 implies 44.5% upside from the current price of $33.61.
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $31.93 | ↓ 5.00% |
1-day model range: $31.69–$32.17. Peak: $32.17 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · MDLN · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-03 | Baird | Maintains | Outperform→Outperform |
| 2026-06-01 | Barclays | Maintains | Overweight→Overweight |
| 2026-05-14 | BNP Paribas | Maintains | Neutral→Neutral |
| 2026-05-13 | Tigress Financial | Maintains | Buy→Buy |
| 2026-05-07 | Citigroup | Maintains | Buy→Buy |
| 2026-05-07 | Bernstein | Maintains | Outperform→Outperform |
| 2026-05-07 | BTIG | Maintains | Buy→Buy |
| 2026-03-10 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-03-09 | Tigress Financial | Maintains | Buy→Buy |
| 2026-03-09 | BTIG | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Medline Inc. (MDLN) stock. Of the recent 17 rating actions, 0 were upgrades and 0 were downgrades. 14 analysts currently cover MDLN.
Analyst Recommendation Trends
MDLN analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 5 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$31.1B
↓ 13.8% YoY
Revenue Next Year
$33.6B
↑ 8.0% YoY
EPS This Year
$1.51
EPS Next Year
$1.66
↑ 9.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast MDLN EPS of $1.51 for the current fiscal year, based on estimates from 15 analysts. The MDLN revenue forecast is $31.1B for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The MDLN stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MDLN price target is $48.55 (+44.5% upside), with an analyst consensus of Buy.
The MDLN short-term stock prediction for tomorrow is $31.93 (-5.00%).
Medline Inc. trades on NASDAQ under the ticker MDLN. The MDLN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 86% of covering analysts.
Frequently asked questions
MDLN forecast · 8 questionsAccording to 14 Wall Street analysts, the average 12-month MDLN price target is $48.55, with a high forecast of $60.00 and a low of $38.00. The median price target is shown in the chart above when available. This implies +44.5% potential upside from the current price of $33.61.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.